Critical Survey: Biodesix (NASDAQ:BDSX) & Aeon Global Health (OTCMKTS:AGHC)

Aeon Global Health (OTCMKTS:AGHC) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Aeon Global Health and Biodesix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aeon Global Health	N/A	N/A	N/A	N/A	N/A
Biodesix	$65.56 million	2.55	-$52.15 million	($0.39)	-2.95

Aeon Global Health has higher earnings, but lower revenue than Biodesix.

Insider & Institutional Ownership

21.0% of Biodesix shares are owned by institutional investors. 11.5% of Aeon Global Health shares are owned by insiders. Comparatively, 69.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Aeon Global Health and Biodesix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aeon Global Health	N/A	N/A	N/A
Biodesix	-66.84%	-275.79%	-43.05%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Aeon Global Health and Biodesix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aeon Global Health	0	0	0	0	0.00
Biodesix	0	0	5	0	3.00

Biodesix has a consensus target price of $3.06, suggesting a potential upside of 166.09%. Given Biodesix’s stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Aeon Global Health.

Summary

Biodesix beats Aeon Global Health on 6 of the 9 factors compared between the two stocks.

About Aeon Global Health

AEON Global Health Corp. is a growth oriented provider of personalized, actionable medical informatics, and telemedicine. It offers a comprehensive menu of diagnostic and laboratory developed assays, as well as interpretive data for a range of inherited conditions. The company was founded by Hanif A. Roshan and Shawn Desai in August 1985 and is headquartered in Gainesville, GA.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.